188 related articles for article (PubMed ID: 11688965)
1. Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.
Murata K; Sudo T; Kameyama M; Fukuoka H; Muka M; Doki Y; Sasaki Y; Ishikawa O; Kimura Y; Imaoka S
Clin Exp Metastasis; 2000; 18(7):599-604. PubMed ID: 11688965
[TBL] [Abstract][Full Text] [Related]
2. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
[TBL] [Abstract][Full Text] [Related]
3. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
7. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
8. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
McEwan DG; Brunton VG; Baillie GS; Leslie NR; Houslay MD; Frame MC
Cancer Res; 2007 Jun; 67(11):5248-57. PubMed ID: 17545604
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
Torphy TJ; Zhou HL; Cieslinski LB
J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058
[TBL] [Abstract][Full Text] [Related]
10. The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Gordeladze JO
Biosci Rep; 1990 Aug; 10(4):375-88. PubMed ID: 2174276
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents.
Zhang B; Yang L; Konishi Y; Maeda N; Sakanaka M; Tanaka J
Neuropharmacology; 2002 Feb; 42(2):262-9. PubMed ID: 11804623
[TBL] [Abstract][Full Text] [Related]
13. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
14. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
15. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Zhao H; Quilley J; Montrose DC; Rajagopalan S; Guan Q; Smith CJ
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2973-81. PubMed ID: 17293498
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of phosphodiesterase isoforms III or IV suppress islet-cell nitric oxide production.
Beshay E; Prud'homme GJ
Lab Invest; 2001 Aug; 81(8):1109-17. PubMed ID: 11502862
[TBL] [Abstract][Full Text] [Related]
20. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]